Prostate cancer (PCa) is the second most prevalent cancer in men. In 2020, approximately
1,414,259 new cases were reported that accounted for 3, 75,324 deaths (Sung et al. in CA …

Background The use of biomarkers for prostate cancer screening, diagnosis and prognosis
has the potential to improve the clinical management of the patients. Owing to inherent …

Since the introduction of serum prostate-specific antigen (PSA) screening 25 years ago,
prostate cancer diagnosis and management have been guided by this biomarker. Yet, PSA …

The application of prostate-specific antigen (PSA) in prostate cancer (PC) screening,
diagnosis, and prognosis has improved the clinical management of PC patients. However …

Prostate cancer: current status Prostate cancer (PCa) is the most common non-cutaneous
malignancy in men and is responsible for the second most common age-adjusted death rate …

Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most
patients do not die from the disease. Prostate specific antigen (PSA), the most widely used …

Prostate cancer (PCa) is the most commonly diagnosed solid tumor among men in the
United States and Europe. Even without treatment, PCa-specific mortality rates at 5 and 10 …

Prostate cancer is a heterogeneous disease with disparate outcomes. Traditional clinical
parameters are limited in their ability to differentiate between these cases, and there is …

Prostate cancer (PCa) is one of the leading causes of cancer death among males, especially
in more developed countries. Diagnosis is often achieved at an early stage of the disease …

ABSTRACT Introduction Prostate cancer (PCa) is one of the most frequently diagnosed
malignancies worldwide and is associated with high mortality. Broad screening through …